http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Feb 2026 08:05:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html <p align="justify">Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZSgpr5o9vJ1t4eeVQ-_cAQS0543ActyMs3KJDcufUrAM94BGSyzG3aFX9tGkxpHDWVdFjzBgBRucB_HewAzmkj9bwxpGAUg7Sp45tuZ2F4eP822-TgU-w7lRCDInL3-pFAsRsgfpndpJHqtuZNkFPFGPaPZ-lzMtPuvw54x7Qak=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for http://www.streetinsider.com/Press+Releases/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html Mon, 02 Feb 2026 08:05:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html <p align="justify">Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZSgpr5o9vJ1t4eeVQ-_cAQS0543ActyMs3KJDcufUrAM94BGSyzG3aFX9tGkxpHDWVdFjzBgBRucB_HewAzmkj9bwxpGAUg7Sp45tuZ2F4eP822-TgU-w7lRCDInL3-pFAsRsgfpndpJHqtuZNkFPFGPaPZ-lzMtPuvw54x7Qak=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for http://www.streetinsider.com/Press+Releases/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html Mon, 02 Feb 2026 08:05:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html <p align="justify">Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZSgpr5o9vJ1t4eeVQ-_cAQS0543ActyMs3KJDcufUrAM94BGSyzG3aFX9tGkxpHDWVdFjzBgBRucB_HewAzmkj9bwxpGAUg7Sp45tuZ2F4eP822-TgU-w7lRCDInL3-pFAsRsgfpndpJHqtuZNkFPFGPaPZ-lzMtPuvw54x7Qak=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for http://www.streetinsider.com/Press+Releases/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html Mon, 02 Feb 2026 08:05:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html <p align="justify">Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZSgpr5o9vJ1t4eeVQ-_cAQS0543ActyMs3KJDcufUrAM94BGSyzG3aFX9tGkxpHDWVdFjzBgBRucB_HewAzmkj9bwxpGAUg7Sp45tuZ2F4eP822-TgU-w7lRCDInL3-pFAsRsgfpndpJHqtuZNkFPFGPaPZ-lzMtPuvw54x7Qak=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for http://www.streetinsider.com/Globe+Newswire/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html Mon, 02 Feb 2026 08:05:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html <p align="justify">Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZSgpr5o9vJ1t4eeVQ-_cAQS0543ActyMs3KJDcufUrAM94BGSyzG3aFX9tGkxpHDWVdFjzBgBRucB_HewAzmkj9bwxpGAUg7Sp45tuZ2F4eP822-TgU-w7lRCDInL3-pFAsRsgfpndpJHqtuZNkFPFGPaPZ-lzMtPuvw54x7Qak=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for http://www.streetinsider.com/Globe+Newswire/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html Mon, 02 Feb 2026 08:05:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html <p align="justify">Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZSgpr5o9vJ1t4eeVQ-_cAQS0543ActyMs3KJDcufUrAM94BGSyzG3aFX9tGkxpHDWVdFjzBgBRucB_HewAzmkj9bwxpGAUg7Sp45tuZ2F4eP822-TgU-w7lRCDInL3-pFAsRsgfpndpJHqtuZNkFPFGPaPZ-lzMtPuvw54x7Qak=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for http://www.streetinsider.com/Globe+Newswire/In+Spaceflight+Conditions%3A+N2OFF%E2%80%98s+MitoCareX+Bio+Highlights+Co-Founder%26apos%3Bs+Innovative+Research+on+Mitochondrial+Carriers+in+Microgravity+and+Cosmic+radiation+Conditions/25927629.html Mon, 02 Feb 2026 08:05:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html <p><i>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ibi_14h65YwZe1eFzjYdxGc_5NEBZbxC0Mi0h-bcDw3DwO2pxZq-wkYkcz3wmw0T-eDRsjTgOZosNbdVAkbNKwgJgCnY1q6hJH-o_uE2uafYz_idWAEwe3Cgwq21AqALZcJV3eeNyvimF_uoF_la54FU4CkFvTeVeHdj4IBWl7kJ0P_XkhQF25VkH9DlsnRnLdQXVH404laN1o5WTSTAaA==" rel="nofollow" target="_blank"><i>Inflammatory Metabolic Diseases</i></a> – A Market Projected to Exceed $120 billion by 2030</p> <p align="justify">Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kdzqutghYSF5fFYfa4GjghTboqbVLF2xdpmIMbzMSeZmZGp632IqWC22Y9GeQqOwFVgvy4T4GCvnkJsV1Y6n80V6OcA67XowtcVMmuotZQ8k72I-_-vRBAtzxbB90Zw5Xn6BX_5t34UkIDIiXBzPEdrwwPfB6SrO7MurycogT-k=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has http://www.streetinsider.com/Press+Releases/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html Thu, 22 Jan 2026 07:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html <p><i>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ibi_14h65YwZe1eFzjYdxGc_5NEBZbxC0Mi0h-bcDw3DwO2pxZq-wkYkcz3wmw0T-eDRsjTgOZosNbdVAkbNKwgJgCnY1q6hJH-o_uE2uafYz_idWAEwe3Cgwq21AqALZcJV3eeNyvimF_uoF_la54FU4CkFvTeVeHdj4IBWl7kJ0P_XkhQF25VkH9DlsnRnLdQXVH404laN1o5WTSTAaA==" rel="nofollow" target="_blank"><i>Inflammatory Metabolic Diseases</i></a> – A Market Projected to Exceed $120 billion by 2030</p> <p align="justify">Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kdzqutghYSF5fFYfa4GjghTboqbVLF2xdpmIMbzMSeZmZGp632IqWC22Y9GeQqOwFVgvy4T4GCvnkJsV1Y6n80V6OcA67XowtcVMmuotZQ8k72I-_-vRBAtzxbB90Zw5Xn6BX_5t34UkIDIiXBzPEdrwwPfB6SrO7MurycogT-k=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has http://www.streetinsider.com/Press+Releases/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html Thu, 22 Jan 2026 07:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html <p><i>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ibi_14h65YwZe1eFzjYdxGc_5NEBZbxC0Mi0h-bcDw3DwO2pxZq-wkYkcz3wmw0T-eDRsjTgOZosNbdVAkbNKwgJgCnY1q6hJH-o_uE2uafYz_idWAEwe3Cgwq21AqALZcJV3eeNyvimF_uoF_la54FU4CkFvTeVeHdj4IBWl7kJ0P_XkhQF25VkH9DlsnRnLdQXVH404laN1o5WTSTAaA==" rel="nofollow" target="_blank"><i>Inflammatory Metabolic Diseases</i></a> – A Market Projected to Exceed $120 billion by 2030</p> <p align="justify">Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kdzqutghYSF5fFYfa4GjghTboqbVLF2xdpmIMbzMSeZmZGp632IqWC22Y9GeQqOwFVgvy4T4GCvnkJsV1Y6n80V6OcA67XowtcVMmuotZQ8k72I-_-vRBAtzxbB90Zw5Xn6BX_5t34UkIDIiXBzPEdrwwPfB6SrO7MurycogT-k=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has http://www.streetinsider.com/Press+Releases/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html Thu, 22 Jan 2026 07:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html <p><i>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ibi_14h65YwZe1eFzjYdxGc_5NEBZbxC0Mi0h-bcDw3DwO2pxZq-wkYkcz3wmw0T-eDRsjTgOZosNbdVAkbNKwgJgCnY1q6hJH-o_uE2uafYz_idWAEwe3Cgwq21AqALZcJV3eeNyvimF_uoF_la54FU4CkFvTeVeHdj4IBWl7kJ0P_XkhQF25VkH9DlsnRnLdQXVH404laN1o5WTSTAaA==" rel="nofollow" target="_blank"><i>Inflammatory Metabolic Diseases</i></a> – A Market Projected to Exceed $120 billion by 2030</p> <p align="justify">Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kdzqutghYSF5fFYfa4GjghTboqbVLF2xdpmIMbzMSeZmZGp632IqWC22Y9GeQqOwFVgvy4T4GCvnkJsV1Y6n80V6OcA67XowtcVMmuotZQ8k72I-_-vRBAtzxbB90Zw5Xn6BX_5t34UkIDIiXBzPEdrwwPfB6SrO7MurycogT-k=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has http://www.streetinsider.com/Globe+Newswire/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html Thu, 22 Jan 2026 07:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html <p><i>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ibi_14h65YwZe1eFzjYdxGc_5NEBZbxC0Mi0h-bcDw3DwO2pxZq-wkYkcz3wmw0T-eDRsjTgOZosNbdVAkbNKwgJgCnY1q6hJH-o_uE2uafYz_idWAEwe3Cgwq21AqALZcJV3eeNyvimF_uoF_la54FU4CkFvTeVeHdj4IBWl7kJ0P_XkhQF25VkH9DlsnRnLdQXVH404laN1o5WTSTAaA==" rel="nofollow" target="_blank"><i>Inflammatory Metabolic Diseases</i></a> – A Market Projected to Exceed $120 billion by 2030</p> <p align="justify">Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kdzqutghYSF5fFYfa4GjghTboqbVLF2xdpmIMbzMSeZmZGp632IqWC22Y9GeQqOwFVgvy4T4GCvnkJsV1Y6n80V6OcA67XowtcVMmuotZQ8k72I-_-vRBAtzxbB90Zw5Xn6BX_5t34UkIDIiXBzPEdrwwPfB6SrO7MurycogT-k=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has http://www.streetinsider.com/Globe+Newswire/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html Thu, 22 Jan 2026 07:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html <p><i>MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ibi_14h65YwZe1eFzjYdxGc_5NEBZbxC0Mi0h-bcDw3DwO2pxZq-wkYkcz3wmw0T-eDRsjTgOZosNbdVAkbNKwgJgCnY1q6hJH-o_uE2uafYz_idWAEwe3Cgwq21AqALZcJV3eeNyvimF_uoF_la54FU4CkFvTeVeHdj4IBWl7kJ0P_XkhQF25VkH9DlsnRnLdQXVH404laN1o5WTSTAaA==" rel="nofollow" target="_blank"><i>Inflammatory Metabolic Diseases</i></a> – A Market Projected to Exceed $120 billion by 2030</p> <p align="justify">Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kdzqutghYSF5fFYfa4GjghTboqbVLF2xdpmIMbzMSeZmZGp632IqWC22Y9GeQqOwFVgvy4T4GCvnkJsV1Y6n80V6OcA67XowtcVMmuotZQ8k72I-_-vRBAtzxbB90Zw5Xn6BX_5t34UkIDIiXBzPEdrwwPfB6SrO7MurycogT-k=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has http://www.streetinsider.com/Globe+Newswire/N2OFF%3A+MitoCareX+Bio+Announces+Positive+In+Vitro+Results+from+Its+Mitochondrial+Carrier+Small+Molecule+Platform/25878222.html Thu, 22 Jan 2026 07:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html <p align="justify">Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=opp6UA0l6Ov5friJUWSw0JG1hYO05sHtFw6xf51oPRT9vg4EYOQYSwyx9fsoVF6KwluMHaumpHfo1Lp_ALOF33ODW0cWdfka2jCbHS6bPeaphbH4DwarLuann2P4wfslfgPoKuTit7HZ3seRdF0xlDBztFyRaxSzD7Mw2Wkxa7I=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.</p> <p http://www.streetinsider.com/Press+Releases/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html Thu, 15 Jan 2026 08:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html <p align="justify">Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=opp6UA0l6Ov5friJUWSw0JG1hYO05sHtFw6xf51oPRT9vg4EYOQYSwyx9fsoVF6KwluMHaumpHfo1Lp_ALOF33ODW0cWdfka2jCbHS6bPeaphbH4DwarLuann2P4wfslfgPoKuTit7HZ3seRdF0xlDBztFyRaxSzD7Mw2Wkxa7I=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.</p> <p http://www.streetinsider.com/Press+Releases/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html Thu, 15 Jan 2026 08:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html <p align="justify">Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=opp6UA0l6Ov5friJUWSw0JG1hYO05sHtFw6xf51oPRT9vg4EYOQYSwyx9fsoVF6KwluMHaumpHfo1Lp_ALOF33ODW0cWdfka2jCbHS6bPeaphbH4DwarLuann2P4wfslfgPoKuTit7HZ3seRdF0xlDBztFyRaxSzD7Mw2Wkxa7I=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.</p> <p http://www.streetinsider.com/Press+Releases/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html Thu, 15 Jan 2026 08:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html <p align="justify">Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=opp6UA0l6Ov5friJUWSw0JG1hYO05sHtFw6xf51oPRT9vg4EYOQYSwyx9fsoVF6KwluMHaumpHfo1Lp_ALOF33ODW0cWdfka2jCbHS6bPeaphbH4DwarLuann2P4wfslfgPoKuTit7HZ3seRdF0xlDBztFyRaxSzD7Mw2Wkxa7I=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.</p> <p http://www.streetinsider.com/Globe+Newswire/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html Thu, 15 Jan 2026 08:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html <p align="justify">Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=opp6UA0l6Ov5friJUWSw0JG1hYO05sHtFw6xf51oPRT9vg4EYOQYSwyx9fsoVF6KwluMHaumpHfo1Lp_ALOF33ODW0cWdfka2jCbHS6bPeaphbH4DwarLuann2P4wfslfgPoKuTit7HZ3seRdF0xlDBztFyRaxSzD7Mw2Wkxa7I=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.</p> <p http://www.streetinsider.com/Globe+Newswire/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html Thu, 15 Jan 2026 08:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Globe+Newswire/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html <p align="justify">Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=opp6UA0l6Ov5friJUWSw0JG1hYO05sHtFw6xf51oPRT9vg4EYOQYSwyx9fsoVF6KwluMHaumpHfo1Lp_ALOF33ODW0cWdfka2jCbHS6bPeaphbH4DwarLuann2P4wfslfgPoKuTit7HZ3seRdF0xlDBztFyRaxSzD7Mw2Wkxa7I=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.</p> <p http://www.streetinsider.com/Globe+Newswire/N2OFF%3A%C2%A0MitoCareX+Bio+Spotlights+Co-Founder%26apos%3Bs+Pioneering+Research+on+Mitochondrial+Carriers+in+Spaceflight+Stress+Conditions/25852975.html Thu, 15 Jan 2026 08:32:00 -0500 80W NITO O.08047001 http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Press+Releases/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC http://www.streetinsider.com/Globe+Newswire/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html <p align="justify">Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gFurgyGnEt6pNQr2-q_kNZf6OwIygFlhBjFTWf94ar8Uz2z886FaKm3hLxLYARUxAcDp2Re7C9fRqZUsQJ4IL9DO0JBtEVyN9tiFzFE-ZIl8MbLvyXkQ4Bw77X1Tt9I3T_9bZn6baakzFo1ChGFjkJPfkweH7X3ZQnwPY6nWovo=" rel="nofollow" target="_blank">RTB (Ready to Build)</a> business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cQ4Bkepw5pFAiJVAeCJfnNRUId26kVQhBmtFCEVtnSvG31LRgIPPuPquSi6DQhXYb8aATvwHqOM9SDXwENj6ew==" rel="nofollow" target="_blank">MitoCareX</a><a target="_blank" href="https://www.globenewswire.com/Tracker?data=z_sCOIKsiot3GeMbslFMY1Yg22HUbIdoXZ_AjZUXVUf2OFXAaWmyIh5Ksqx8LssjIN-2j9hoBzNzLHExZeXI6g==" rel="nofollow" target="_blank"> Bio Ltd</a>. (&quot;MitoCareX&quot;), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the http://www.streetinsider.com/Globe+Newswire/N2OFF+Stockholders+Approve+Merger+with+Drug+Discovery+Company+Targeting+Resistant+Cancers+Including+Pancreatic+and+Non-Small+Cell+Lung+Cancer/25378312.html Thu, 25 Sep 2025 16:01:00 -0500 80W A.25552276 NITO O.06196855 O.08047001 SPRC